CAMP signaling regulates platelet myosin light chain (MLC) phosphorylation and shape change through targeting the RhoA-Rho kinase-MLC phosphatase signaling pathway

Blood

Volumn 122, Issue 20, 2013, Pages 3533-3545

  Aburima, Ahmed ^a   Wraith, Katie S ^a   Raslan, Zaher ^a   Law, Robert ^a   Magwenzi, Simbarashe ^a   Naseem, Khalid M ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT; CYCLIC AMP DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT BETA; MULTIENZYME COMPLEX; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN PHOSPHATASE; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1 DELTA; PROSTAGLANDIN E1; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE 2; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SERINE; THREONINE; THROMBIN; UNCLASSIFIED DRUG; CYCLIC AMP DEPENDENT PROTEIN KINASE; MULTIPROTEIN COMPLEX; MYOSIN LIGHT CHAIN KINASE; PHOSPHOSERINE; PHOSPHOTHREONINE; PPP1R12A PROTEIN, HUMAN; PROTEIN SUBUNIT; RHOA PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN;

ARTICLE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE SHAPE; BLOOD; CELL SHAPE; DRUG EFFECTS; ENZYMOLOGY; IN VITRO STUDY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN SUBUNIT; SECOND MESSENGER; THROMBOCYTE; ULTRASTRUCTURE;

ALPROSTADIL; BLOOD PLATELETS; CELL SHAPE; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; IN VITRO TECHNIQUES; MULTIPROTEIN COMPLEXES; MYOSIN-LIGHT-CHAIN KINASE; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PHOSPHORYLATION; PHOSPHOSERINE; PHOSPHOTHREONINE; PROTEIN PHOSPHATASE 1; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN SUBUNITS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION; THROMBIN;

EID: 84892400602     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-487850     Document Type: Article

References (53)

1. Hartwig JH, Barkalow K, Azim A, Italiano J. The elegant platelet: signals controlling actin assembly. Thromb Haemost. 1999;82(2): 392-398.
2. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989;69(1):58-178.
3. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol. 1999;144(4): 745-754.
4. Lokeshwar VB, Bourguignon LY. The involvement of Ca21 and myosin light chain kinase in collagen-induced platelet activation. Cell Biol Int Rep. 1992;16(9):883-897.
5. Oury C, Sticker E, Cornelissen H, De Vos R, Vermylen J, Hoylaerts MF. ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca21-calmodulin and myosin light chain kinase activation. J Biol Chem. 2004;279(25):26266-26273.
6. Riondino S, Gazzaniga PP, Pulcinelli FM. Convulxin induces platelet shape change through myosin light chain kinase and Rho kinase. Eur J Biochem. 2002;269(23): 5878-5884.
7. Hathaway DR, Eaton CR, Adelstein RS. Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMPdependent protein kinase. Nature. 1981; 291(5812):252-256.
8. Daniel JL, Molish IR, Rigmaiden M, Stewart G. Evidence for a role of myosin phosphorylation in the initiation of the platelet shape change response. J Biol Chem. 1984;259(15): 9826-9831.
9. Suzuki Y, Yamamoto M, Wada H, et al. Agonistinduced regulation of myosin phosphatase activity in human platelets through activation of Rhokinase. Blood. 1999;93(10):3408-3417.
10. Bauer M, Retzer M, Wilde JI, et al. Dichotomous regulation of myosin phosphorylation and shape change by Rhokinase and calcium in intact human platelets. Blood. 1999;94(5):1665-1672.
11. Paul BZ, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem. 1999;274(40):28293-28300.
12. Wraith KS, Magwenzi S, Aburima A, Wen Y, Leake D, Naseem KM. Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways. Blood. 2013;122(4): 580-589.
13. Hartshorne DJ, Ito M, Erdödi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil. 1998; 19(4):325-341.
14. Smolenski A. Novel roles of cAMP/cGMPdependent signaling in platelets. J Thromb Haemost. 2012;10(2):167-176.
15. Pannocchia A, Hardisty RM. Cyclic AMP inhibits platelet activation independently of its effect on cytosolic free calcium. Biochem Biophys Res Commun. 1985;127(1):339-345.
16. Graber SE, Hawiger J. Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets. J Biol Chem. 1982; 257(24):14606-14609.
17. Feinstein MB, Fraser C. Human platelet secretion and aggregation induced by calcium ionophores. Inhibition by PGE1 and dibutyryl cyclic AMP. J Gen Physiol. 1975;66(5):561-581.
18. Salzman EW, Kensler PC, Levine L. Cyclic 3′,5′-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function. Ann N Y Acad Sci. 1972;201: 61-71.
19. Sim DS, Merrill-Skoloff G, Furie BC, Furie B, Flaumenhaft R. Initial accumulation of platelets during arterial thrombus formation in vivo is inhibited by elevation of basal cAMP levels. Blood. 2004;103(6):2127-2134.
20. Gerry ABSL, Satchell L, Leake DS. A novel method for production of lipid hydroperoxide- or oxysterol-rich low-density lipoprotein. Atherosclerosis. 2008;197(2):579-587.
21. Roberts W, Magwenzi S, Aburima A, Naseem KM. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood. 2010;116(20):4297-4306.
22. Hall KJ, Jones ML, Poole AW. Coincident regulation of PKCdelta in human platelets by phosphorylation of Tyr311 and Tyr565 and phospholipase C signalling. Biochem J. 2007; 406(3):501-509.
23. McAvoy T, Nairn AC. Chapter 18: Unit 18. Serine/threonine protein phosphatase assays. In: Ausubel FM, Brent R, Kingston RE, et al, eds. Current Protocols in Molecular Biology. Hoboken, NJ: Wiley; 2010.
24. Jones RL, Wise H, Clark R, Whiting RL, Bley KR. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations. Br J Pharmacol. 2006; 149(1):110-120.
25. Gambaryan S, Geiger J, Schwarz UR, et al. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood. 2004;103(7):2593-2600.
26. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000;57(5):976-983.
27. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol. 2005;168(6):941-953.
28. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351(Pt 1):95-105.
29. Ren XD, Kiosses WB, Schwartz MA. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 1999; 18(3):578-585.
30. Manganello JM, Djellas Y, Borg C, Antonakis K, Le Breton GC. Cyclic AMP-dependent phosphorylation of thromboxane A(2) receptorassociated Galpha(13). J Biol Chem. 1999; 274(39):28003-28010.
31. Schoenwaelder SM, Burridge K. Evidence for a calpeptin-sensitive protein-tyrosine phosphatase upstream of the small GTPase Rho. A novel role for the calpain inhibitor calpeptin in the inhibition of protein-tyrosine phosphatases. J Biol Chem. 1999;274(20): 14359-14367.
32. Schoenwaelder SM, Petch LA, Williamson D, Shen R, Feng G-S, Burridge K. The protein tyrosine phosphatase Shp-2 regulates RhoA activity. Curr Biol. 2000;10(23): 1523-1526.
33. Forget MA, Desrosiers RR, Gingras D, Béliveau R. Phosphorylation states of Cdc42 and RhoA regulate their interactions with Rho GDP dissociation inhibitor and their extraction from biological membranes. Biochem J. 2002;361(Pt 2):243-254.
34. Ellerbroek SM, Wennerberg K, Burridge K. Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem. 2003;278(21): 19023-19031.
35. Lang P, Gesbert F, Delespine-Carmagnat M, Stancou R, Pouchelet M, Bertoglio J. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 1996;15(3): 510-519.
36. Dong JM, Leung T, Manser E, Lim L. cAMPinduced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKalpha. J Biol Chem. 1998;273(35): 22554-22562.
37. Adamson P, Paterson HF, Hall A. Intracellular localization of the P21rho proteins. J Cell Biol. 1992;119(3):617-627.
38. Takaishi K, Sasaki T, Kameyama T, Tsukita S, Tsukita S, Takai Y. Translocation of activated Rho from the cytoplasm to membrane ruffling area, cell-cell adhesion sites and cleavage furrows. Oncogene. 1995;11(1): 39-48.
39. Rolli-Derkinderen M, Sauzeau V, Boyer L, et al. Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res. 2005; 96(11):1152-1160.
40. Qiao J, Huang F, Lum H. PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2003;284(6): L972-L980.
41. Casey PJ, Thissen JA, Moomaw JF. Enzymatic modification of proteins with a geranylgeranyl isoprenoid. Proc Natl Acad Sci USA. 1991;88(19): 8631-8635.
42. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol. 1999;147(5):1023-1038.
43. Rowley JW, Oler AJ, Tolley ND, et al. Genomewide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118(14): e101-e111.
44. Patil SB, Tsunoda Y, Pawar MD, Bitar KN. Translocation and association of ROCK-II with RhoA and HSP27 during contraction of rabbit colon smooth muscle cells. Biochem Biophys Res Commun. 2004;319(1):95-102.
45. Shin HM, Je HD, Gallant C, Tao TC, Hartshorne DJ, Ito M, Morgan KG. Differential association and localization of myosin phosphatase subunits during agonist-induced signal transduction in smooth muscle. Circ Res. 2002; 90(5):546-553.
46. Pleines IHI, Hagedorn I, Gupta S, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood. 2012;119(4):1054-1063.
47. Gratacap MP, Payrastre B, Nieswandt B, Offermanns S. Differential regulation of Rho and Rac through heterotrimeric G-proteins and cyclic nucleotides. J Biol Chem. 2001;276(51): 47906-47913.
48. Murthy KS, Zhou H, Grider JR, Makhlouf GM. Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am J Physiol Gastrointest Liver Physiol. 2003;284(6): G1006-G1016.
49. Nakamura K, Koga Y, Sakai H, Homma K, Ikebe M. cGMP-dependent relaxation of smooth muscle is coupled with the change in the phosphorylation of myosin phosphatase. Circ Res. 2007;101(7): 712-722.
50. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273(5272): 245-248.
51. Wilson DP, Susnjar M, Kiss E, Sutherland C, Walsh MP. Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca21 entry and Ca21 sensitization: Rho-associated kinase-mediated phosphorylation of MYPT1 at Thr-855, but not Thr-697. Biochem J. 2005;389(Pt 3):763-774.
52. Nakai K, Suzuki Y, Kihira H, et al. Regulation of myosin phosphatase through phosphorylation of the myosin-binding subunit in platelet activation. Blood. 1997;90(10):3936-3942.
53. Azam MA, Yoshioka K, Ohkura S, Takuwa N, Sugimoto N, Sato K, Takuwa Y. Ca21-independent, inhibitory effects of cyclic adenosine 5′-monophosphate on Ca21 regulation of phosphoinositide 3-kinase C2alpha, Rho, and myosin phosphatase in vascular smooth muscle. J Pharmacol Exp Ther. 2007;320(2):907-916.